Klebsiella
infections
include different types of infections like bloodstream infections; pneumonia;
wound or surgical site infections; and meningitis, caused by the Klebsiella
bacteria. The symptoms associated with these infections are high fevers,
chills, cough, and shortness of breath.
Hospitalized
patients undergoing treatment for other conditions may be susceptible to these
infections. In healthcare settings, patients who require long courses of
antibiotics, or are treated with devices like ventilators or intravenous
catheters are at a high risk of developing these infections.
Although
these infections are often treated with antibiotics, but some Klebsiella
bacteria may be resistant to certain types of antibiotics. Arsanis Inc. is in
the process of developing ASN300 as a monoclonal antibody for the treatment of
Klebsiella infections.
Make
Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1065
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment